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and treating osteoporosis in postmenopausal women (PW). In
addition, these are the ﬁrst option of treatment (the Spanish Bone
and Mineral Society -SEIOMM) in the Clinical Practice Guide-
lines (GPC) (2003). Here, we analyse the evolution of con-
sumption of bisphosphonates and raloxifene in Spanish PW
(over 50), during the period 1999 to 2004. METHODS: A ret-
rospective analysis of the consumption was made, selecting the
four drugs for osteoporosis in PW treatment. Paget’s disease data
were not included. Drug consumption data were provided by the
Ministry of Health and Consume Database. The ﬁgures are pre-
sented as number of dispensed units (standard package), as
numbers of DDDs / 1000 PW / day, according to the ATC/DDD
system, Index 2006, and as Euros (Price to Customer tax-free) /
Dispensed DDDs / 1000 PW / day. Demographics were consulted
in the Spanish INE Database. RESULTS: The number of dis-
pensed units of Alendronate, Risedronate and Raloxifene
between 2003 and 2004 were 43.41%, 126.62%, and 19.75%,
respectively. Only Etidronate decreased, but only a 9.64%. From
among the results to emphasize the ﬁgures of DDDs / 1000 
PW / day between 2003 and 2004 that show also this increases
(15.87%, 60.18%, and 1.45% for Alendronate, Risedronate and
Raloxifene, respectively). Alendronate presented the higher cost
in 2004 (€12,297,15/DDDs/1000 PW/day. CONCLUSIONS:
The indicators used in this study have permitted establish that
dispensing data of osteoporosis in PW treatment ﬁnanced by
Spanish NHS had a signiﬁcant increase in 2004. These data coin-
cide with the implement of the Spanish GPC.
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OBJECTIVES: Adoption of new drug in medical care, a highly-
regulated industry, is and essential in terms of access to new
treatment option and raise on health care expenditure. This
study, using Cox2 as example, is to examine the diffusion of new
drug among hospitals of different characteristics. METHOD:
The data were drawn from systematic random sample of NHI
claim data in 1997 to 2001. We applied the Bass diffusion model
to analyze the monthly number of each hospital’s outpatient
clinic visits with COX2. Bass diffusion model based on the initial
time of purchase of product to explains the behavior of the dif-
fusion of the product in the market: length to reach maximum
monthly volume, maximum monthly volume, growth rate.
RESULTS: The estimates of Bass diffusion model shows that the
monthly numbers of outpatient clinic visits with COX2 pre-
scription reached the stable maximum in the 92th month, 41
months after the introduction of COX2 on April of 2001. The
length of growth period for reaching maximum volume varied
with different accreditation level of hospital: academic medical
center 38 months, metropolitan hospitals 43 months, local com-
munity hospitals 40 months, and physician clinics 51 months.
The average of maximum volume for academic center was 76.17
outpatient visits, metropolitan hospitals 87.25 visits, local com-
munity hospitals 62.65 visits, and physician clinics 34.38 visits.
Physician clinics has the fast growth rate (q = 0.1278), in con-
trast to the slowest of local community hospitals (q = 0.1159),
CONCLUSION: Hospitals of different level vary in terms of
adopting new drugs. Academic medical centers play the role of
innovators.
POS13
THE ESTIMATION OF COST–EFFECTIVENESS THRESHOLDS
PRIOR TO THE START OF LARGE CLINICAL STUDIES
Van Staa TP1, Cooper C2, Leufkens HG3
1General Practice Research Database, London, UK, 2University of
Southampton, Southampton, UK, 3Utrecht University, Utrecht,The
Netherlands
OBJECTIVES: Cost-effectiveness analyses are currently con-
ducted after the conduct of expensive clinical trials. An approach
was developed to estimate cost-effectiveness thresholds prior to
clinical studies, comparable to statistical power calculations.
METHODS: A new osteoporosis treatment was taken as
example, with different scenarios of treatment efﬁcacy and costs.
Data on fracture and mortality risks were obtained from the
General Practice Research Database. These risks were estimated
individually by age, sex, fracture history, body mass index,
smoking and other risk factors. EQ5D utilities were obtained
from a UK national report (NICE) and outcomes were simulated
over a 10-year period (5-year treatment), using a cost-
acceptability ratio of £30k per QALY gained. RESULTS: The 
5-year risk of osteoporotic fracture required to reach the cost-
effectiveness threshold was 17.1% (95% conﬁdence interval
15.0–19.3%) with a fracture efﬁcacy of 0.50 at an annual cost
of £1000. This was 6.1% (5.2–7.0%) with a cost of £250 and
3.7% (3.1–4.5% with a cost of £100. With a fracture efﬁcacy of
only 0.80, these threshold risks were 34.7% (23.2–38.7%),
10.7% (8.3–14.5%) and 5.4% (3.8–7.8%), respectively. At a T-
score of −2.5 and fracture efﬁcacy of 0.80 and cost of £250,
patients without a fracture history would require additional risk
factors (with a relative rate of 2.5) in order to reach the thresh-
old, while this would be reached by the average woman at 
age 85. However, with a cost of £1000, this threshold would
only be reached at age 55 with additional risk factors with 
RR of 9.5 and at age 85 with RR of 3.0. CONCLUSION: Cost-
effectiveness thresholds can be estimated prior to expensive clin-
ical trials using high-quality health care databases. Similar to
statistical power calculations, they can then be used to guide
patient selection into the clinical trials, by providing information
on the required minimum levels of risks.
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OBJECTIVES: To assess changes in health related quality of life
(HRQoL) in patients with osteoporotic hip fracture in Poland
using EQ-5D. METHODS: 104 patients (82 women and 22 men;
mean age 80.1 years), hospitalized between March 2004 and
March 2005, with osteoporotic hip fracture were included in a
prospective clinical trial. The inclusion criteria was: age at least
60 years, low energy femoral neck fracture or pertrochanteric
fracture of the femur and absence of severe cognitive dysfunc-
tion as measured by Hodkinson’s Abbreviated Mental Test Score.
Quality of life was measured with descriptive part of Polish
version of generic questionnaire EQ-5D. The reference European
value set (BIOMED) was used. During the ﬁrst 72 hours after
hospitalisation, patients were asked to rate their HRQoL during
the month before fracture. The follow-up took place at 10 days
and 14 months after the injury. RESULTS: Eighty three patients
were avaiable at the ﬁnal follow-up (11 were ceased and 10 lost
to follow-up). Mean EQ-5D Index increased signiﬁcantly 14
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months after the injury comparing with direct postfracture value:
from 21.6 pts to 45.9 pts, but was signiﬁcantly lower than before
fracture −72.4 pts. At the ﬁnal follow-up, according to descrip-
tive part of EQ-5D: 91.5% of patients had problems with
walking about and with washing or dressing self, 87.9%—had
limitations performing usual activities and 74.7% had pain or
discomfort. Patients treated conservatively experienced mean
reduction of EQ-5D Index by 47.7 points, treated with Ender
nails—by 35.3, with hemiarthroplasty—by 26.5, with total hip
replacement—by 20.4 and with dynamic hip screw—by 10.3
points. CONCLUSIONS: Hip fracture leads to signiﬁcant QoL
reduction, observed even at 14 months after the injury. Major
disabilities include walking and washing or dressing self. Con-
servative treatment and ﬁxation with Ender nails lead to highest
HRQoL reduction.
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OBJECTIVES: The aim of our prospective study is to compare
health state score of patients with femoral neck fracture at the
time of primary treatment in hospital and at 1.5 years after treat-
ment by using EQ-5D questionnaire. METHODS: The validated
version of EQ-5D questionnaire was ﬁlled in at ﬁrst on the 6–8th
day after primary treatment of femoral neck fracture in hospi-
tals, than later 1.5 years after surgical treatment at home.
Patients ﬁlled in the questionnaires with the assistance of inter-
viewer at 6–8th day and it was posted to them 1.5 years later to
their home (control value). Patients with polytrauma were
excluded from the study. We compared the health state score of
patient ﬁlled in both questionnaires according to gender, activ-
ity (active/non active), marital status (married/single), education
(high school/or lower), residence (town/village), type of opera-
tion (osteosynthesis/prosthesis). RESULTS: Altogether 134
patients (97 women and 37 men) ﬁll in both questionnaires.
Their mean age was 73.05 ± 10.75 years (min.40 years, max 92
years). The mean health statues score of all patients was 0.548
at 6–8th day and 0.433 at 1.5 years later. According to gender:
female: 0.539 and 0.451; male: 0.572 and 0.383 (statistical test:
P = 0.205). Type of operation: ostheosynthesis: 0.395 and 0.437;
arthroplasty: 0.605 and 0.431 (P = 0.073). Residence: town:
0.598 and 0.494; village: 0.5 and 0.373 (P = 0.053). Education:
at least high school: 0.651 and 0.456; below high school: 0.482
and 0.417 (P = 0.160). Marital status: single: 0.481 and 0.418;
married: 0.629 and 0.452 (P = 0.303). Activity: non active: 0.537
and 0.423; active: 0.702 and 0.518 (P = 0.278). Age (P:0057).
CONCLUSIONS: The personal opinion on health status showed
a deterioration 1.5 years following femoral neck fracture, which
is determined mainly by age, residence, type of operation and
education. Our study will be completed later by inclusion health
status data from visual analogue scale.
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OBJECTIVES: There are few studies investigating the conse-
quences of fractures in terms of health outcomes. A large
prospective Swedish study (KOFOR) assessed quality of life
related to fractures of the hip, spine, wrist the ﬁrst 12 months
after fracture. Data were collected using a questionnaire admin-
istered by nurses at seven study centres in Sweden. The study
indicated that spine fractures are associated with lower quality
of life than previously assumed. The purpose of this study is to
investigate the long term quality of life data based on the period
13–18 months after fracture. METHODS: A total of 684
patients survived the whole 18 month period and were thus
included in the analysis (hip:283, vertebral:76, wrist:325).
Patients were asked about their quality of life (EQ-5D) directly
after the fracture, at 4 months, 12 months and after 18 months.
Recollected QOL before the fracture was also collected.
RESULTS: Results show that the QOL-levels reached after 12
months (0.69, 0.49, and 0.88 for hip, spine and wrist respec-
tively) were almost constant after 18 months (0.72, 0.51 and
0.90) indicating that there are persistent QOL-losses associated
with osteoporotic fractures. Pre-fracture QOL-values were 0.81,
0.74 and 0.90 for hip, spine and wrist, respectively. A spine frac-
tures are associated with lower long term quality of life levels
than previously assumed, and the loss from a spine fracture
doubles that of a hip fracture. CONCLUSIONS: Hip and verte-
bral fractures carries long term effects on QOL and the long term
effects of spine fractures are more severe than previously known.
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OBJECTIVES: Describe patient characteristics, health related
quality of life and back pain in postmenopausal women with
severe osteoporosis who are initiating teriparatide in France.
METHODS: The European Forsteo® Observational Study,
EFOS is a 36-month, prospective study evaluating fracture out-
comes, back pain and health-related quality of life in post-
menopausal women with osteoporosis initiating teriparatide.
Patients were enrolled in Austria, Denmark, France, Germany,
Greece, Ireland, The Netherlands, and Sweden. Design was non-
interventional with all consenting patients in the course of
normal clinical practice intiiating teriparatide being eligible for
enrolment. QOL was assessed with the EQ-5D questionnaire,
pain was assessed with the back pain questionnaire and a visual
analogue scale (VAS). RESULTS: A total of 309 patients were
enrolled in the study in France. The mean (SD) age was 74.5
(7.4) years. A total of 96.8% of patients had 2 or more fractures
after 40 years old and 77.5% of the pre-existing fractures were
vertebral ones. In 82.8% of cases, BMD T-score for lumbar
spine, total hip and femoral neck was under −2.5. Back pain was
frequently observed: 76.6% of patients stating that they had
back pain every day or almost every day. Intensity of back pain
was moderate to severe in 93.1% of cases. Back pain led to lim-
itation of activities moderately or severely in 83.1% of cases. The
corresponding mean (SD) visual analogue scale score for exist-
ing back pain in the last month was 56.2 (24.9). Patients QOL
was also deteriorated with a median EQ-5D health state value
of 0.52 and 30.7% of patients reporting extreme problems with
pain and discomfort and 15.5% reporting extreme problems
with usual activities. CONCLUSIONS: The proﬁle of the EFOS
study cohort indicates that patients initiating teriparatide have
severe osteoporosis associated with back pain impacting on usual
daily activities and a poor quality of life.
